A dose-escalating, dose-ranging study of the safety, tolerability, and immunogenicity of a bivalent influenza peptide conjugate vaccine formulated with aluminum- and iscomatrix containing adjuvants (BIPCV/IMX) evaluated in healthy adults 18 to 35 years of age.

Trial Profile

A dose-escalating, dose-ranging study of the safety, tolerability, and immunogenicity of a bivalent influenza peptide conjugate vaccine formulated with aluminum- and iscomatrix containing adjuvants (BIPCV/IMX) evaluated in healthy adults 18 to 35 years of age.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2015

At a glance

  • Drugs V 512 (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Merck & Co
  • Most Recent Events

    • 04 Nov 2009 Planned number of patients changed from 241 to 187 as reported by ClinicalTrials.gov
    • 04 Nov 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 23 Feb 2009 New source identified and integrated (ClinicalTrials.gov): study phase identified and status updated to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top